HEPION PHARMACEUTICALS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- HEPION PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2017-06-30 was $0.00.
- HEPION PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2017-03-31 was $4.10K, a 464.46% increase year-over-year.
- HEPION PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2016-12-31 was $25.00K.
- HEPION PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2016-09-30 was $2.18K, a 93.47% decline year-over-year.
- HEPION PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2017 was $31.28K, a 8.26% decline from fiscal 2016.
- HEPION PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2016 was $34.09K, a 2665.04% increase from fiscal 2015.
- HEPION PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2015 was $1.23K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2017-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $31.28K 10-K · filed 2019-03-14 |
| 2017-03-31 | $4.10K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-04-12 | $31.28K derived: sum of 4 quarters · filed 2018-03-26 |
| 2016-12-31 | $25.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-14 | $27.91K derived: sum of 4 quarters · filed 2018-03-26 |
| 2016-09-30 | $2.18K 10-Q · filed 2016-11-14 | $2.91K derived: sum of 4 quarters · filed 2018-03-26 |
| 2016-06-30 | $0.00 derived: 10-KT 12 month − 10-Q 9 month · filed 2018-03-26 | $34.09K 10-KT · filed 2018-03-26 |
| 2016-03-31 | $726.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-13 | |
| 2015-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-12 | |
| 2015-09-30 | $33.37K 10-Q · filed 2015-11-12 | |
| 2015-06-30 | $1.23K 10-K · filed 2016-09-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |